Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days. The event is scheduled for April 26, 2023, at 11:00 AM ET. C4T is focused on advancing targeted protein degradation science to develop small-molecule medicines aimed at transforming disease treatment. Through its innovative TORPEDO® platform, C4T is designing therapies that leverage the body’s protein recycling system to degrade disease-causing proteins, addressing challenges like drug resistance. A live webcast of the chat will be available on C4T's website, along with an archived replay for 30 days post-event.